• 1
    Magheli A, Rais-Bahrami S, Trock BJ et al. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol 2008; 179: 17804
  • 2
    Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 8156
  • 3
    Freedland SJ, Wieder JA, Jack GS et al. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 2002; 168: 1105
  • 4
    Jones TD, Koch MO, Bunde PJ et al. Is prostate specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy? BJU Int 2006; 97: 4804
  • 5
    Radwan MH, Yan Y, Luly JR et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 2007; 69: 11217
  • 6
    Magheli A, Hinz S, Hege C et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010; 183: 12631
  • 7
    Tsuzuki T, Hernandez DJ, Aydin H et al. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 2005; 173: 4503
  • 8
    Nakanishi H, Troncoso P, Babaian RJ. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater. J Urol 2008; 180: 24416
  • 9
    World Health Organization, Western Pacific Region, International Association for the Study of Obesity. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Australia Health Communications Australia Pty, Limited, 2000
  • 10
    D'Amico AV, Renshaw AA, Arsenault L et al. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy. Int J Radiat Oncol Biol Phys 1999; 45: 8416
  • 11
    Kulkarni GS, Lockwood G, Evans A et al. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer 2007; 109: 24328
  • 12
    Gofrit ON, Zorn KC, Taxy JB et al. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol 2007; 178: 19258
  • 13
    Dong F, Jones JS, Stephenson AJ et al. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179: 896900
  • 14
    Thong AE, Shikanov S, Katz MH et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy-can we predict adverse pathological outcomes? J Urol 2008; 180: 243640
  • 15
    Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 2005; 23: 754654
  • 16
    Kassouf W, Nakanishi H, Ochiai A et al. Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J Urol 2007; 178: 1114
  • 17
    Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 2005; 66: 122933
  • 18
    Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29: 366976
  • 19
    Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 124853